BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22173550)

  • 21. Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Date K; Ohtsuka T; Fujimoto T; Tamura K; Kimura H; Matsunaga T; Mochidome N; Miyazaki T; Mori Y; Oda Y; Nakamura M; Tanaka M
    Ann Surg; 2017 May; 265(5):969-977. PubMed ID: 28398963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fucosylation is associated with the malignant transformation of intraductal papillary mucinous neoplasms: a lectin microarray-based study.
    Watanabe K; Ohta M; Yada K; Komori Y; Iwashita Y; Kashima K; Inomata M
    Surg Today; 2016 Oct; 46(10):1217-23. PubMed ID: 26754572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo and in vitro propagation of intraductal papillary mucinous neoplasms.
    Kamiyama H; Kamiyama M; Hong SM; Karikari CA; Lin MT; Borges MW; Griffith M; Young A; Norris-Kirby A; Lubek C; Mizuma M; Feldmann G; Shi C; Liang H; Goggins MG; Maitra A; Hruban RH; Eshleman JR
    Lab Invest; 2010 May; 90(5):665-73. PubMed ID: 20231822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas.
    Paini M; Crippa S; Partelli S; Scopelliti F; Tamburrino D; Baldoni A; Falconi M
    World J Gastroenterol; 2014 Aug; 20(29):10008-23. PubMed ID: 25110429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma.
    Fritz S; Fernandez-del Castillo C; Mino-Kenudson M; Crippa S; Deshpande V; Lauwers GY; Warshaw AL; Thayer SP; Iafrate AJ
    Ann Surg; 2009 Mar; 249(3):440-7. PubMed ID: 19247032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
    Molin MD; Matthaei H; Wu J; Blackford A; Debeljak M; Rezaee N; Wolfgang CL; Butturini G; Salvia R; Bassi C; Goggins MG; Kinzler KW; Vogelstein B; Eshleman JR; Hruban RH; Maitra A
    Ann Surg Oncol; 2013 Nov; 20(12):3802-8. PubMed ID: 23846778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas.
    Adsay NV; Merati K; Basturk O; Iacobuzio-Donahue C; Levi E; Cheng JD; Sarkar FH; Hruban RH; Klimstra DS
    Am J Surg Pathol; 2004 Jul; 28(7):839-48. PubMed ID: 15223952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.
    Chang X; Yu C; Li J; Yu S; Chen J
    Int J Med Sci; 2017; 14(5):412-418. PubMed ID: 28539816
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
    Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
    Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.
    Kuroki H; Hayashi H; Okabe H; Hashimoto D; Takamori H; Nakahara O; Nakagawa S; Fukushima Y; Chikamoto A; Beppu T; Hirota M; Iyama K; Baba H
    PLoS One; 2014; 9(8):e100904. PubMed ID: 25084021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
    Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
    Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid.
    Hata T; Dal Molin M; McGregor-Das A; Song TJ; Wolfgang C; Eshleman JR; Hruban RH; Goggins M
    J Mol Diagn; 2018 Jan; 20(1):46-55. PubMed ID: 29229290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical role of Notch signaling pathway in intraductal papillary mucinous neoplasm of the pancreas.
    Ikemoto T; Sugimoto K; Shimada M; Utsunomiya T; Morine Y; Imura S; Arakawa Y; Kanamoto M; Iwahashi S; Saito Y; Yamada S
    J Gastroenterol Hepatol; 2015 Jan; 30(1):217-22. PubMed ID: 25041344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs.
    Jansen M; Fukushima N; Rosty C; Walter K; Altink R; Heek TV; Hruban R; Offerhaus JG; Goggins M
    Cancer Biol Ther; 2002; 1(3):293-6. PubMed ID: 12432281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.
    Iacobuzio-Donahue CA; Klimstra DS; Adsay NV; Wilentz RE; Argani P; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Am J Pathol; 2000 Sep; 157(3):755-61. PubMed ID: 10980115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features.
    Shimizu T; Akita M; Sofue K; Toyama H; Itoh T; Fukumoto T; Zen Y
    Hum Pathol; 2019 Sep; 91():26-35. PubMed ID: 31175918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.
    Attiyeh MA; Fernández-Del Castillo C; Al Efishat M; Eaton AA; Gönen M; Batts R; Pergolini I; Rezaee N; Lillemoe KD; Ferrone CR; Mino-Kenudson M; Weiss MJ; Cameron JL; Hruban RH; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Wolfgang CL; Allen PJ
    Ann Surg; 2018 Jan; 267(1):157-163. PubMed ID: 28079542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic mucinous noncystic (colloid) carcinomas and intraductal papillary mucinous carcinomas are usually microsatellite stable.
    Lüttges J; Beyser K; Pust S; Paulus A; Rüschoff J; Klöppel G
    Mod Pathol; 2003 Jun; 16(6):537-42. PubMed ID: 12808058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.